Business
Karo Healthcare enters an exclusive license agreement with Moberg Pharma for MOB-015 in Europe
Karo Healthcare AB ("Karo") has entered an exclusive licensing agreement with Moberg Pharma AB ("Moberg Pharma") regarding the commercialisation of MOB-015 in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key European markets under the leading global antifungal brand Lamisil®1.
About this update from Karooooo Ltd.
[{"type":"text","content":"STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Karo Healthcare AB ("Karo") has entered an exclusive licensing agreement with Moberg Pharma AB ("Moberg Pharma") regarding the commercialisation of MOB-015 in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key European markets under the leading global antifungal brand Lamisil®1.","length":386,"tagName":"p"},{"type":"text","content":"The agreement covers 19 markets, representing a total population of approximately 500 million people, including all major EU countries and the United Kingdom ("Big 5"). It also includes eleven countries where MOB-015 is already approved but not yet launched. In these markets, Karo will be responsible for marketing, distribution, and sales.","length":351,"tagName":"p"},{"type":"text","content":"The agreement further strengthens our position in the foot health category, one of Karo's core focus areas, where we already have established brands and deep expertise across commercial execution, consumer insights, and regulatory know-how.","length":244,"tagName":"p"},{"type":"text","content":"MOB-015, developed by Moberg Pharma, represents the next generation of terbinafine therapy – a new topical formulation. Previous attempts at topical treatment with terbinafine have failed due to the difficulty of delivering a sufficient amount of the active substance through the nail. MOB-015 is the first topical treatment to achieve results on par with oral treatment, with 76% of patients reaching mycological cure in registration studies. It is therefore particularly satisfying to launch the product under the strong and fitting Lamisil® brand in most of the 19 countries.","length":578,"tagName":"p"},{"type":"text","content":""Moberg Pharma has developed a clinically well-documented and differentiated product. Being able to launch MOB-015 under the strong Lamisil® brand makes this a powerful combination of scientific innovation and commercial execution — and positions us strongly to lead in the European antifungal market," says Christoffer Lorenzen, CEO of Karo.","length":352,"tagName":"p"},{"type":"text","content":""We are very pleased to enter this partnership with Karo, which has a strong commercial presence across Europe. Launching MOB-015 under the well-known Lamisil® brand gives us...